Therefore, NRF2 activators and/or SIRT activators have been proposed as possible treatment agents for a broad range of viral infections, including respiratory virus infections such as RSV, COVID-19, influenza, adenoviruses, and many other viruses [155,166]. This evidence concerns the gene NFE2L2 and viral infectious disease.